Nineteen nail dystrophy in an atopic background responsive to dupilumab: a case report
- 1Department of Dermatology, The First Hospital of Hebei Medical University , , ,
Abstract
Onychodystrophy refers to abnormal nail structure or growth arising from disorders affecting the nail unit. Published reports of pediatric nail dystrophy occurring in an atopic background remain limited. We report a 7-year-old boy whose nail abnormalities were first noted at 3 weeks of age, progressively involved 19 of the 20 fingernails and toenails in the persistent absence of any eczematous lesions. Following an inadequate response to prior conventional therapies, the nail abnormalities showed marked improvement after 8 months of dupilumab therapy. In this patient, AD-associated nail involvement was considered a possible diagnosis after exclusion of common alternative causes, and the marked response to dupilumab further strengthened this possibility. This case highlights the importance of a broad differential diagnosis for pediatric nail dystrophy and suggests that dupilumab may be a therapeutic option when an atopic contribution is clinically suspected.
Related
- Vitiligo developing during dupilumab treatment in a child with atopic dermatitis: a case report and literature review
- Roflumilast Cream for Residual Disease in Patients With Atopic Dermatitis on Dupilumab: A Retrospective Chart Review Study
- Impact of Dupilumab Therapy on Skin Barrier Function in Patients With Moderate-to-Severe Atopic Dermatitis: A Phase IV, Non-Randomized, Open-Label, Parallel-Group Clinical Study.
- Dupilumab in Atopic Dermatitis – Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry
- Long‐Term Ocular Outcomes of Dupilumab in Atopic Dermatitis: Results From the BioDay Registry
BibTeX
@article{zang2026nineteen,
title = {{Nineteen nail dystrophy in an atopic background responsive to dupilumab: a case report}},
author = {Yilan Zang and Xingmo Li and Huichao Li and Jinxu Qi and Qing Zhu and Guoqiang Zhang},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1938551},
url = {https://europepmc.org/article/PMC/PMC13724647},
note = {CC BY},
}
RIS
TY - JOUR
TI - Nineteen nail dystrophy in an atopic background responsive to dupilumab: a case report
AU - Yilan Zang
AU - Xingmo Li
AU - Huichao Li
AU - Jinxu Qi
AU - Qing Zhu
AU - Guoqiang Zhang
PY - 2026
DA - 2026/10/19
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1938551
UR - https://europepmc.org/article/PMC/PMC13724647
AB - Onychodystrophy refers to abnormal nail structure or growth arising from disorders affecting the nail unit. Published reports of pediatric nail dystrophy occurring in an atopic background remain limited. We report a 7-year-old boy whose nail abnormalities were first noted at 3 weeks of age, progressively involved 19 of the 20 fingernails and toenails in the persistent absence of any eczematous lesions. Following an inadequate response to prior conventional therapies, the nail abnormalities showed marked improvement after 8 months of dupilumab therapy. In this patient, AD-associated nail involvement was considered a possible diagnosis after exclusion of common alternative causes, and the marked response to dupilumab further strengthened this possibility. This case highlights the importance of a broad differential diagnosis for pediatric nail dystrophy and suggests that dupilumab may be a therapeutic option when an atopic contribution is clinically suspected.
SN - 2296-858X
ER -